{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=17",
    "query": {
      "intervention": "Phase 2 Maximum Tolerated Dose determined in Phase 1",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 507,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T02:18:37.962Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00393965",
      "title": "Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Neoplasms"
      ],
      "interventions": [
        {
          "name": "MPC-6827",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2005-12",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-02-13",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00393965"
    },
    {
      "nct_id": "NCT00002909",
      "title": "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "oral sodium phenylbutyrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1997-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002909"
    },
    {
      "nct_id": "NCT00005067",
      "title": "Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage I Prostate Cancer",
        "Stage IIA Prostate Cancer",
        "Stage IIB Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "motexafin lutetium",
          "type": "DRUG"
        },
        {
          "name": "photodynamic therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2000-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005067"
    },
    {
      "nct_id": "NCT01033240",
      "title": "CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Liver Cancer",
        "Hepatic Cancer",
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "CS-1008 2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "CS-1008 6/2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "CS-1008 6/6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "CS-1008 4 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "CS-1008 6 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2010-07-09",
      "completion_date": "2013-09-09",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01033240"
    },
    {
      "nct_id": "NCT04234048",
      "title": "Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Cutaneous/Peripheral T-Cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Classified",
        "Primary Cutaneous T-cell Lymphoma",
        "Cutaneous T-Cell Lymphoma, Unspecified",
        "Cutaneous T-cell Lymphoma",
        "Follicular T-Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Sézary's Disease",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SciTech Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2023-12-18",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234048"
    },
    {
      "nct_id": "NCT06480565",
      "title": "A Phase 1/2 Trial of ADI-270 in ccRCC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-270",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adicet Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-12",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06480565"
    },
    {
      "nct_id": "NCT01497093",
      "title": "Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-02-15",
      "completion_date": "2019-07-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497093"
    },
    {
      "nct_id": "NCT01717898",
      "title": "A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castrate-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "BEZ235",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charles Ryan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2013-01-31",
      "completion_date": "2016-08-29",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01717898"
    },
    {
      "nct_id": "NCT04209790",
      "title": "Neoadjuvant Chemoradiation for Resectable Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Surgery",
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant chemoradiation",
          "type": "RADIATION"
        },
        {
          "name": "Drug Therapy with Temozolomide (benzolamide) (Standard of Care)",
          "type": "DRUG"
        },
        {
          "name": "Surgery post Radiation and Temozolomide (benzolamide)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Geisinger Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-04-01",
      "completion_date": "2022-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 2,
      "location_summary": "Danville, Pennsylvania • Wilkes-Barre, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        },
        {
          "city": "Wilkes-Barre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04209790"
    },
    {
      "nct_id": "NCT05240898",
      "title": "A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RO7623066",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2021-08-26",
      "completion_date": "2025-11-26",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-15T02:18:37.962Z",
      "location_count": 15,
      "location_summary": "Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Maine"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05240898"
    }
  ]
}